BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 22948895)

  • 1. Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension.
    Eechoute K; van der Veldt AA; Oosting S; Kappers MH; Wessels JA; Gelderblom H; Guchelaar HJ; Reyners AK; van Herpen CM; Haanen JB; Mathijssen RH; Boven E
    Clin Pharmacol Ther; 2012 Oct; 92(4):503-10. PubMed ID: 22948895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib.
    Kim JJ; Vaziri SA; Rini BI; Elson P; Garcia JA; Wirka R; Dreicer R; Ganapathi MK; Ganapathi R
    Cancer; 2012 Apr; 118(7):1946-54. PubMed ID: 21882181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of polymorphisms in angiogenesis-related genes as predictive and prognostic markers for sunitinib-treated metastatic renal cell carcinoma patients.
    Dornbusch J; Walter M; Gottschalk A; Obaje A; Junker K; Ohlmann CH; Meinhardt M; Zacharis A; Zastrow S; Schoffer O; Grimm MO; Klug SJ; Wirth MP; Fuessel S
    J Cancer Res Clin Oncol; 2016 Jun; 142(6):1171-82. PubMed ID: 26935927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.
    Rini BI; Cohen DP; Lu DR; Chen I; Hariharan S; Gore ME; Figlin RA; Baum MS; Motzer RJ
    J Natl Cancer Inst; 2011 May; 103(9):763-73. PubMed ID: 21527770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypertension as a predictive factor for survival outcomes in patients with metastatic renal cell carcinoma treated with sunitinib after progression on cytokines.
    Szmit S; Langiewicz P; Złnierek J; Nurzyński P; Zaborowska M; Filipiak KJ; Opolski G; Szczylik C
    Kidney Blood Press Res; 2012; 35(1):18-25. PubMed ID: 21849795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib.
    Scartozzi M; Bianconi M; Faloppi L; Loretelli C; Bittoni A; Del Prete M; Giampieri R; Maccaroni E; Nicoletti S; Burattini L; Minardi D; Muzzonigro G; Montironi R; Cascinu S
    Br J Cancer; 2013 Mar; 108(5):1126-32. PubMed ID: 23511629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib.
    Beuselinck B; Lambrechts D; Van Brussel T; Wolter P; Cardinaels N; Joniau S; Lerut E; Karadimou A; Couchy G; Sebe P; Ravaud A; Zerbib M; Caty A; Paridaens R; Schöffski P; Verkarre V; Berger J; Patard JJ; Zucman-Rossi J; Oudard S
    Acta Oncol; 2014 Oct; 53(10):1413-22. PubMed ID: 24874929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma.
    Diekstra MH; Liu X; Swen JJ; Boven E; Castellano D; Gelderblom H; Mathijssen RH; Rodríguez-Antona C; García-Donas J; Rini BI; Guchelaar HJ
    Eur J Clin Pharmacol; 2015 Dec; 71(12):1477-84. PubMed ID: 26387812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of single nucleotide polymorphisms on treatment outcomes and toxicity in patients treated with sunitinib.
    Maeng CH; Yi JH; Lee J; Hong JY; Choi MK; Jung HA; Park JO; Park SH; Park YS; Kang WK; Lim HY
    Anticancer Res; 2013 Oct; 33(10):4619-26. PubMed ID: 24123039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypertension and Circulating Cytokines and Angiogenic Factors in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma Treated With Sunitinib: Results From a Phase II Trial.
    Bilen MA; Zurita AJ; Ilias-Khan NA; Chen HC; Wang X; Kearney AY; Hodges S; Jonasch E; Huang S; Khakoo AY; Tannir NM
    Oncologist; 2015 Oct; 20(10):1140-8. PubMed ID: 26306901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
    Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
    J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels.
    Kappers MH; van Esch JH; Sluiter W; Sleijfer S; Danser AH; van den Meiracker AH
    Hypertension; 2010 Oct; 56(4):675-81. PubMed ID: 20733093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experience with sunitinib treatment for metastatic renal cell carcinoma in a large cohort of Israeli patients: outcome and associated factors.
    Livne-Segev D; Gottfried M; Maimon N; Peer A; Neumann A; Hayat H; Kovel S; Sella A; Mermershtain W; Rouvinov K; Boursi B; Weitzen R; Berger R; Keizman D
    Isr Med Assoc J; 2014 Jun; 16(6):347-51. PubMed ID: 25058995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib.
    van der Veldt AA; Eechoute K; Gelderblom H; Gietema J; Guchelaar HJ; van Erp NP; van den Eertwegh AJ; Haanen JB; Mathijssen RH; Wessels JA
    Clin Cancer Res; 2011 Feb; 17(3):620-9. PubMed ID: 21097692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.
    Xie M; He CS; Huang JK; Lin QZ
    Eur J Cancer; 2015 Mar; 51(5):595-603. PubMed ID: 25618828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sunitinib-induced hypertension in CYP3A4 rs4646437 A-allele carriers with metastatic renal cell carcinoma.
    Diekstra MH; Belaustegui A; Swen JJ; Boven E; Castellano D; Gelderblom H; Mathijssen RH; García-Donas J; Rodríguez-Antona C; Rini BI; Guchelaar HJ
    Pharmacogenomics J; 2017 Jan; 17(1):42-46. PubMed ID: 26810136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.
    Park SJ; Lee JL; Park I; Park K; Ahn Y; Ahn JH; Lee DH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
    Chemotherapy; 2012; 58(6):468-74. PubMed ID: 23548259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of sunitinib-induced hypertension in solid tumor by nitric oxide donors.
    León-Mateos L; Mosquera J; Antón Aparicio L
    Redox Biol; 2015 Dec; 6():421-425. PubMed ID: 26386874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction in skin microvascular density and changes in vessel morphology in patients treated with sunitinib.
    van der Veldt AA; de Boer MP; Boven E; Eringa EC; van den Eertwegh AJ; van Hinsbergh VW; Smulders YM; Serné EH
    Anticancer Drugs; 2010 Apr; 21(4):439-46. PubMed ID: 20051825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rho kinase inhibition mitigates sunitinib-induced rise in arterial pressure and renal vascular resistance but not increased renal sodium reabsorption.
    Grisk O; Koenen A; Meissner T; Donner A; Braun D; Steinbach A; Glöckl G; Zimmermann U; Evert K; Evert M; Katsari E; Löhn M; Plettenburg O; Rettig R
    J Hypertens; 2014 Nov; 32(11):2199-210; discussion 2110. PubMed ID: 25275248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.